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Introduction: Estrogen (E2) delays onset and decreases severity of experimental arthritis. The aim of this study was
to investigate the importance of total estrogen receptor alpha (ERα) expression and cartilage-specific ERα expression
in genetically modified mice for the ameliorating effect of estrogen treatment in experimental arthritis.
Methods: Mice with total (total ERα−/−) or cartilage-specific (Col2α1-ERα−/−) inactivation of ERα and wild-type (WT)
littermates were ovariectomized, treated with E2 or placebo, and induced with antigen-induced arthritis (AIA). At
termination, knees were collected for histology, synovial and splenic cells were investigated by using flow cytometry,
and splenic cells were subjected to a T-cell proliferation assay.
Results: E2 decreased synovitis and joint destruction in WT mice. Amelioration of arthritis was associated with
decreased frequencies of inflammatory cells in synovial tissue and decreased splenic T-cell proliferation. E2 did not
affect synovitis or joint destruction in total ERα−/− mice. In Col2α1-ERα−/− mice, E2 protected against joint destruction
to a similar extent as in WT mice. In contrast, E2 did not significantly ameliorate synovitis in Col2α1-ERα−/− mice.
Conclusions: Treatment with E2 ameliorates both synovitis and joint destruction in ovariectomized mice with AIA via
ERα. This decreased severity in arthritis is associated with decreased synovial inflammatory cell frequencies and reduced
splenic T-cell proliferation. ERα expression in cartilage is not required for estrogenic amelioration of joint destruction.
However, our data indicate that ERα expression in cartilage is involved in estrogenic effects on synovitis, suggesting
different mechanisms for the amelioration of joint destruction and synovitis by E2.Introduction
Rheumatoid arthritis (RA) is an autoimmune disease
characterized by a massive infiltration of mononuclear
and polymorphonuclear cells into the joints and the
development of inflammation that results in synovitis
and destruction of articular cartilage and adjacent bone
loss [1].
The mechanisms that give rise to RA are only partly
understood, and several different immune cells, including
lymphocytes, macrophages, and neutrophils, are involved.* Correspondence: cecilia.engdahl@rheuma.gu.se
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stated.Furthermore, a number of inflammatory mediators are
implicated in the establishment and progression of
arthritis, including proinflammatory cytokines such as
tumor necrosis factor alpha (TNFα) and interleukin
(IL)-6 and IL-17 [2,3].
RA affects 0.5% to 1% of the population [4], and the
female-to-male ratio is 3:1. Estrogen plays an important
role in the pathogenesis of RA, and we and others have
demonstrated, in different experimental arthritis models,
that estrogen delays the onset and decreases the severity
of the disease [5-8]. However, the role of estrogen in
inflammatory diseases is complex [9,10], and findings
are contradictory; some human studies have reported no
effect of estrogen, whereas we and others demonstrate
beneficial effects of estrogen on RA [11-14]. Thus, there is
a need to further understand the role of estrogen in RA.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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via the two classic nuclear estrogen receptors (ERs):
ERα and ERβ. Using ER-specific agonists, we have
recently shown that the ameliorating effect of estrogen
on collagen-induced arthritis is mediated mainly via
ERα [5]. ERα is expressed in tissues adjacent to the joint
inflammation, including cartilage and bone [15,16], as well
as in other peripheral tissues involved in the immune
response, including thymus and spleen [17,18]. However,
it is not known via which cell type estrogen mediates its
ameliorating effect on arthritis.
Since long-term estrogen treatment to postmenopausal
women is associated with severe side effects, knowledge
about the mechanism behind the protective effects of
estrogen is of considerable importance in the search for
new treatment strategies for arthritis. In the present
study, antigen-induced arthritis (AIA) was used to
examine the influence of estrogen on arthritis. AIA
shares many of the histological features of RA, such as
leukocyte infiltration and synovitis together with bone
and cartilage destruction [19], and is dependent on
helper T cells, synovial macrophages, and neutrophils
but independent of cytotoxic T cells and B cells [20-23].
To determine the importance of ERα for arthritis, we
induced AIA in genetically modified mice lacking ERα
expression in all cells. Furthermore, since estrogen can
exert direct effects on cartilage via ERα [16], we used mice
lacking ERα specifically in chondrocytes to determine
the importance of local cartilage-specific ERα expression
for the protective effects of estrogen on arthritis. By
evaluating the estrogenic response in these two models,
we determined the importance of (a) total ERα expression
and (b) cartilage-specific ERα expression in arthritis
amelioration.
We demonstrate that estrogen ameliorates AIA via ERα.
Furthermore, ERα expression in cartilage is not required
for the amelioration of joint destruction. However, our
data indicate that ERα expression in cartilage is involved




The ethics committee for animal experiments at the
University of Gothenburg approved this study. Female
mice were kept, 5 to 10 animals per cage, under standard
environmental conditions and were fed with standard
laboratory chow and tap water ad libitum.
In experiment 1, female C57BL/6 wild-type (WT)
(Scanbur NOVA-SCB AB, Sollentuna, Sweden) mice
were used. In experiment 2, total ERα inactivated mice
(total ERα−/−) and WT littermates were used. Total
ERα−/− mice have a deletion in exon 3 of the ERα gene
and do not express any of the isoforms of the ERα protein.The total ERα−/− mice and corresponding WT (ERα+/+)
littermates were inbred C57BL/6 mice and generated by
breeding male ERα+/− with female ERα+/− mice, obtained
as previously described [24]. In experiment 3, cartilage-
specific ERα inactivated mice and WT littermates were
used. The generation of cartilage-specific ERα inactivated
mice has previously been described, and these mice
have a 62% reduction in ERα protein levels in cartilage
but no reduction in bone or liver [25]. Briefly, mice in
which exon 3 of the ERα gene is flanked by loxP sequences
(ERαflox/flox) were crossed with Col2α1-Cre mice [26] to
generate Col2α1-Cre;ERαflox/+ mice. These mice were
crossed with ERαflox/flox mice to generate conditional
mutants (Col2α1-Cre;ERαflox/flox, hereafter referred to as
Col2α1-ERα−/−) and corresponding littermate controls
(ERαflox/flox). The ERαflox/flox mice are inbred C57BL/6
mice, and the Col2α1-Cre mice were generated on a
B6SJLF1 background and backcrossed more than six times
with C57BL/6 mice.
Ovariectomy and hormone treatment
Total ERα−/− mice have increased sex steroid levels be-
cause of disturbed negative feedback regulation. To avoid
confounding endogenous sex steroid effects and to imitate
a postmenopausal state, all mice were ovariectomized and
treated with placebo or estrogen. Ovariectomy (ovx) was
performed at 10 weeks of age through a midline incision
of the skin and flank incisions of the peritoneum. The
skin incision was closed with metallic clips. Surgery was
performed under anesthesia with isoflurane (Pfizer AB,
Täby, Sweden). Carprofen (OrionPharma, Espoo, Finland)
was used post-operatively as an analgesic.
Ovx mice were inserted with a subcutaneous slow-
release pellet (Innovative Research of America, Sarasota,
FL, USA) with 17β-estradiol (E2) (0.83 μg/day) or placebo.
Mice treated with E2 in a dose similar to the one used
in this study obtain serum E2 levels of approximately
60 pg/mL [27]. In mice, normal serum levels of E2 vary
between 25 and 50 pg/mL in diestrus and between 150
and 200 pg/mL in estrus [28]. Thus, the dose used in
this study resulted in physiological serum E2 levels.
Treatment started at the time of ovx and lasted until
termination.
Induction of antigen-induced arthritis
The mice were immunized with 0.2 mg of methylated
bovine serum albumin (mBSA) (Sigma-Aldrich, Stockholm,
Sweden) dissolved in phosphate-buffered saline (PBS) and
emulsified with an equal volume of complete Freund’s
adjuvant (Sigma-Aldrich). A total volume of 100 μL was
injected intradermally at the base of the tail (50 μL on
each side). After 7 days, mice received an injection with
0.3 mg of mBSA dissolved in 30 μL of vehicle (20% dH2O
and 80% saline) into one knee joint.
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Fourteen days after the primary immunization, the mice
were anaesthetized with Ketalar®/Domitor (PfizerAB), bled,
and killed by cervical dislocation. Serum was individually
stored at −20°C until use. Uteri were collected and weighed.
The knees were separately placed in 4% formaldehyde,
decalcified, and embedded in paraffin. Sections were
stained with eosin/hematoxylin, and a blinded examiner
(CE) graded synovitis and joint destruction. Synovial
hypertrophy was defined as a membrane thickness of
more than two cell layers [29]. A histological scoring
system was used as follows: mild (1), moderate (2), and
severe (3) synovitis and joint destruction. Bone erosions
and cartilage degradation were considered separately in
joint destruction.Single-cell preparation and cellularity measurement
Spleens were harvested, and single-cell suspensions were
obtained after the tissue was mashed and passed through
a 70-μm cell strainer (Becton Dickinson Biosciences
Pharmingen, San Diego, CA, USA) in 15 mL of PBS.
Pelleted cells from spleen were resuspended in Tris-
buffered 0.83% NH4Cl solution to lyse erythrocytes and
washed in PBS. The total number of spleen leukocytes
was analyzed in complete medium (Iscoves medium with
L-glutamin, mercaptoethanol, gentamycin, and fetal
calf serum) (Sigma-Aldrich) by using an automated cell
counter (Sysmex, Hamburg, Germany). Synovial tissue was
dissected and placed in medium (RPMI) (FisherScientific,
Västra Frölunda, Sweden). Medium with DNaseI (Sigma-
Aldrich) and collagenase type IV (Roche AB, Stockholm,
Sweden) was added, and the suspension was incubated
for 1 hour at 37°C. A single-cell suspension was obtained
after the tissue was mashed and passed through a 40-μm
cell strainer (Becton Dickinson) in 4 mL of PBS.Concanavalin A-induced T-cell proliferation in spleen
cell cultures
Isolated splenocytes from experiments 1 to 3 were
suspended in complete medium (1 × 106 cells per mL)
and cultured in round-bottom plates (Nunc, Roskilde,
Denmark) at 37°C, 5% CO2, and 95% humidity. The T-
cell mitogen concanavalin A (conA) (Sigma-Aldrich)
was added to the medium in a final concentration of
1.25 μg/mL, and cells with no added mitogen were used
as controls. After 48 hours of culture, supernatants were
taken from the wells. After an additional 2 hours (in total,
50 hours), 1 μCi[3H] thymidine (Amersham Pharmacia
Biotech, Uppsala, Sweden) was added for 12 hours. Cells
were harvested onto glass fiber filters and counted in a
β-counter (PerkinElmer, Waltham, MA, USA). Cell cul-
tures were set in triplicates, and results are presented
as proliferation index (median of count per minute inwells with conA minus the median of count per minute
in control wells).
Cytokine analysis
Cytokines from the conA-stimulated and control spleen
cell culture supernatants were analyzed by using a Mouse
Th1/Th2 10 plex FlowCytomix Multiplex kit (eBioscience,
San Diego, CA, USA). The cytokine levels of control
supernatants were subtracted from the conA-stimulated
cytokine levels.
Flow cytometry for analysis of cell phenotype
Isolated splenocytes were stained for analysis by using
the following antibodies: BD Horizon V450-conjugated
anti-CD4 (Becton Dickinson) and fluorescein isothio-
cyanate (FITC)-conjugated anti-CD8 (Becton Dickinson).
Synovial cells were examined by using BD Horizon
V450-conjugated anti-CD11b (Becton Dickinson), FITC-
conjugated anti-CD3 (Becton Dickinson), allophycocyanin
(APC)-conjugated anti-F4/80 (BioLegend, San Diego, CA,
USA), Peridinin Chlorophyll Protein Complex (PerCP)-
conjugated anti-CD19 (BioLegend), and phycoerythrin
(PE)-conjugated anti-Gr1. Labeled cells were analyzed in a
FACS CantoII (Becton Dickinson). FlowJo version 8.5.2
(Tree Star, Ashland, OR, USA) software was used for ana-
lyzing the data.
Measurement of mBSA antibodies
Serum was analyzed for mBSA antibodies. IgG type Low
bind Microplates (Nunc) were precoated with 0.1 g/mL
mBSA at 4°C overnight. After coating, the plates were
washed, blocked with 2% casein, and incubated with the
serum. Titration experiments were performed in order
to find the optimal dilution of the sera for enzyme-
linked immunosorbent assay (ELISA) analysis. Biotinyl-
ated F(ab′)2 fragments of goat anti-mouse IgG (Jackson
ImmunoResearch Laboratories, West Grove, PA, USA)
were used as secondary antibody. Bound IgG was de-
tected with a peroxidase-conjugated anti-mouse IgG
(ICN Biochemicals, Aurora, OH, USA) and tetramethyl-
benzidine (Sigma-Aldrich) substrate. Absorbance was
measured at 450 nm on a SpectraMax 340 DC spectro-
photometer (Molecular Devices, Sunnyvale, CA, USA).
Real-time polymerase chain reaction
RNA was isolated from the epiphyseal part of the femur,
containing mainly articular and growth plate chondro-
cytes and trabecular bone, by using an RNeasy kit (Qiagen,
Chatswort, CA, USA). Amplifications were performed
by using the Applied Biosystem StepOnePlus™ Real-Time
PCR System (PE, Applied Biosystems, Stockholm, Sweden)
and Assay-on-Demand primer and probe sets (PE, Applied
Biosystems), labeled with reporter fluorescent dye FAM.
Predesigned primers and probe labeled with reporter
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were included in the reaction as an internal standard.
The assay identification numbers were chemokine CXC
motif ligand 1 (CXCL1): Mm04207460_m1 and chemo-
kine CXC motif ligand 5 (CXCL5): Mm00436451_g1. The
amount of mRNA was calculated by using a standard
curve method in accordance with the instructions of the
manufacturer (PE, Applied Biosystem) and adjusted for
18S ribosomal RNA.
Preparation of peritoneal exudate polymorphonuclear
leukocytes
Inflammation was induced by injecting 0.1 mL of uric
acid solution (10% uric acid in saline) into the peritoneal
cavity of intact Col2α1-ERα−/− and WT littermates [30].
Before injection, the uric acid solution was sonicated for
10 minutes and shaken vigorously. Peritoneal exudate cells
were harvested 4 hours after injection by lavages with cold
PBS. Hypotonic lysis was performed after centrifugation
(200 g for 10 minutes at 4°C) to eliminate red blood
cells, and the cells were washed in Krebs-Ringer glucose
buffer. Nuclear staining using a Scepter™ (EMD Millipore,
Billerica, MA, USA) determined the numbers of peritoneal
exudate cells. The purity of the uric acid-induced periton-
eal exudate cells was 95% polymorphonuclear, and the
remaining cell population was composed of mononuclear
cells [30].
Statistical analysis
For statistical evaluation, Student t tests were performed
for comparison of two independent groups. The histo-
logical scoring was performed by using an ordinal scale
system requiring non-parametric statistical evaluation and
therefore the Mann-Whitney U test was used.
Results
Estrogen decreases antigen-induced arthritis severity
Placebo- and E2-treated ovx mice (experiment 1, see
Materials and methods) were challenged with antigen
according to the regimen illustrated in Figure 1A. E2
treatment was confirmed by increased uterus weight
compared with placebo (740%, P <0.001). Placebo-treated
ovx mice developed severe arthritis in the immunized
knee joint, as revealed by massive cellular infiltration
into the joint space, synovial inflammation, and joint
destruction (Figure 1B,C). Histological examination of
joints from E2-treated ovx mice showed significantly less
joint destruction (bone erosions: −37%, P <0.05; cartilage
degradation: −62%, P <0.01) and synovial inflammation
(−21%, P <0.05) compared with placebo-treated mice,
demonstrating that E2 treatment ameliorates disease
severity in ovariectomized mice (Figure 1B,C).
Synovial cell populations were investigated by using
flow cytometry. E2 treatment significantly decreased thefrequency of neutrophils (−49%, P <0.01) and monocytes/
macrophages (−58%, P <0.01) compared with placebo
treatment (Figure 1D,E). No significant effects were de-
tected in lymphocyte frequencies (Figure 1F,G), although a
tendency to decreased T-cell frequency (−28%, P = 0.051)
was found (Figure 1F). Furthermore, the antigen-specific
antibody response was investigated by measuring serum
levels of mBSA-specific IgG, and similar levels were found
in the placebo- and E2-treated animals (data not shown).
These results suggest that neutrophils and monocytes/
macrophages are involved on a local level in the amelior-
ating effect of E2 on AIA.
Splenocytes from AIA-induced animals were investigated
by using flow cytometry to determine the frequencies of
CD4+ helper T (Th) cells and CD8+ cytotoxic T (Tc) cells.
There was a significant reduction in the frequency of Th
cells (−25%, P <0.05), but no effect on Tc cell frequency
was seen after E2 treatment (Figure 1H). These data are in
accordance with the fact that AIA is dependent on Th,
and not Tc, cells. Splenic proliferation was assessed after
activation with the T-cell mitogen conA. E2 treatment
decreased the proliferation (−32%, P <0.05) compared
with placebo treatment (Figure 1I). To further investigate
the effect of E2 on the peripheral immune response, the
cytokine profile was investigated in supernatants of
conA-stimulated spleen cell cultures. The supernatants
from E2-treated animals showed reduced levels of IL-17
(−51%, P <0.01), IL-2 (−27%, P <0.05), interferon-gamma
(IFN-γ) (−23%, P <0.05), and IL-6 (−28%, P <0.05) versus
placebo treatment, whereas levels of IL-4, TNFα, and GM-
CSF (granulocyte macrophage colony-stimulating factor)
were unchanged (Table 1), demonstrating that E2 treatment
results in an altered systemic cytokine profile which may be
important in the amelioration of arthritis.
Estrogen ameliorates antigen-induced arthritis via ERα
We have previously shown that ERα is important for the
ameliorating effects of estrogen in collagen-induced arth-
ritis and immune-mediated bone loss, using estrogen
receptor-specific agonists [5]. To confirm the requirement
of ERα for the ameliorating effects of E2 treatment on
arthritis by using a genetically modified animal model,
total ERα−/− and their corresponding WT littermates
(experiment 2, see Materials and methods) were chal-
lenged with antigen according to the regimen illustrated
in Figure 1A. E2 treatment significantly increased the
uterus weight of WT littermates (805%, P <0.001), but not
total ERα−/− mice, compared with placebo. There were no
significant differences between placebo-treated WT and
total ERα−/− mice regarding synovitis or joint destruction,
demonstrating that unliganded ERα is not involved in the
development of AIA. As expected, histological examin-
ation of placebo-treated joints in WT littermates revealed
severe arthritis in the immunized knee joints and E2
Figure 1 Estrogen ameliorates antigen-induced arthritis (AIA). (A) Scheme for AIA. Total ERα−/−, Col2α1-ERα−/−, and wild-type (WT) mice were
ovariectomized (OVX) at 10 weeks of age, followed by insertion of slow-release treatment pellets with placebo or estrogen (E2) (0.83 μg/day). Fourteen
days after ovariectomy, the animals were immunized by an intradermal injection of methylated bovine serum (mBSA) emulsified in Freund’s complete
adjuvant (0.2 mg mBSA) and 7 days later given an intra-articular (IA) injection of mBSA (0.3 mg mBSA dissolved in 30 μL of vehicle) in one knee joint.
Seven days after the IA injection, the mice were bled and terminated. (B) Knee joints obtained at termination of WT mice with AIA treated
with placebo or estrogen were examined with a histological scoring of synovitis and joint destruction. The histological examination was performed by
using a scale from 1 to 3: 1, mild; 2, moderate; and 3, severe. *P <0.05, **P <0.01, Mann-Whitney U test. (n = 17-18). (C) Representative images of joint
histology. Percentage of viable (D) neutrophils (CD11b+, Gr1+, F480−), (E) monocytes/macrophages (F480+), (F) T cells (CD3+), and (G) B cells (CD19+)
in synovia tissues. *P <0.05, Student t test (n = 7-8). (H) Percentage of viable CD4+ Th (T helper) cells and CD8+ Tc (T cytotoxic) cells in the spleen.
*P <0.05, Student t test. (n = 17-18). (I) Proliferation of splenocytes after stimulation with the T-cell mitogen concanavalin A (conA). Cell cultures were
set in triplicates, and results are presented as proliferation index (median of count per minute in wells with conA minus the median of count per
minute in control wells). *P <0.05, Student t test (n = 17-18). Results are shown as mean ± standard error of the mean.
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P <0.01; cartilage degradation: −73%, P <0.001) as well as
synovial inflammation (−20%, P <0.01) (Figure 2A,B). In
contrast, E2 treatment did not ameliorate synovitis or
joint destruction in total ERα−/− animals (Figure 2A,B).
This finding demonstrates that ERα is required for the
ameliorating effect of E2 in AIA.
Splenocytes from total ERα−/− mice and WT littermates
were investigated by using flow cytometry. E2 reduced the
frequency of Th cells, but not Tc cells, in WT mice
(−28%, P <0.01), whereas no estrogenic effect was detected
in total ERα−/− animals (Figure 2C). Proliferation was
assessed in splenocytes after activation with the T-cell
mitogen conA. As expected, E2 reduced the proliferation
(−50%, P <0.01) compared with placebo treatment in WT
littermates, whereas no estrogenic effect was detected in
total ERα−/− animals compared with placebo (Figure 2D).
The cytokine profile in supernatants of the proliferation
cultures showed significantly reduced levels of IL-17
(−71%, P <0.01) and IFN-γ (−68%, P <0.05) and tendencies
to reduced levels of IL-2 (−38%, P = 0.075) and IL-6(−36%, P = 0.06) in WT littermates after E2 treatment
compared with placebo treatment (Table 1). In contrast,
E2 did not influence the cytokine pattern in total ERα−/−
animals. These results demonstrate that ERα is required
for the reduced frequency of systemic Th cells, the re-
duced T-cell proliferation, and the altered cytokine profile
seen after E2 treatment.
ERα in cartilage is not required for the ameliorating
effects of estrogen on joint destruction but is involved in
the ameliorating effects of estrogen on synovial
inflammation
Chondrocytes express ERα, and estrogen can exert direct
effects on these cells [16]. Expression of ERα in cartilage
therefore may be involved in the ameliorating effect of
estrogens on AIA. Col2α1-ERα−/− mice, lacking ERα
expression specifically in chondrocytes, and their corre-
sponding WT littermates (experiment 3, see Materials
and methods) were challenged with antigen according
to the regimen illustrated in Figure 1A. Treatment with
E2 significantly induced the uteri weight compared with
Figure 2 Estrogen ameliorates antigen-induced arthritis (AIA) via estrogen receptor alpha (ERα). Total ERα−/− and wild-type (WT) littermates
were treated with placebo or estrogen (E2) (0.83 μg/day) and induced with AIA. (A) Histological scoring of synovitis and joint destruction.
The histological examination was performed by using a scale from 1 to 3: 1, mild; 2, moderate; and 3, severe. *P <0.05, **P <0.01, ***P <0.001
Mann-Whitney U test. (B) Representative images of joint histology. (C) Percentage of viable CD4+ Th (T helper) cells and CD8+ Tc (T cytotoxic)
cells in the spleen. **P <0.01, Student t test. (D) In vitro proliferation of splenocytes, harvested from mice with AIA treated with placebo or E2
(0.83 μg/day), after stimulation with the T-cell mitogen concanavalin A (conA). Cell cultures were set in triplicates, and results are presented as
proliferation index (median of count per minute in wells with conA minus the median of count per minute in control wells). *P <0.05, Student
t test. Results are shown as mean ± standard error of the mean (n = 14-19).
Table 1 Cytokines in supernatants from spleen cell proliferation cultures
(Exp. 1) (Exp. 2) Total ERα−/− (Exp. 3) Col2α1-ERα−/−
(pg/mL) WT WT KO WT KO
IL-17 P 850 ± 107 158 ± 33 97 ± 23 785 ± 158 715 ± 124
E2 417 ± 80a 46 ± 18a 130 ± 41 391 ± 79b 335 ± 103b
IFNγ P 1,039 ± 69 8,881 ± 2,865 7,294 ± 3,192 4,465 ± 1,070 4,782 ± 760
E2 800 ± 54b 2,813 ± 528b 4,926 ± 694 1,622 ± 360b 2,697 ± 340b
IL-2 P 1,038 ± 83 4,355 ± 581 4,098 ± 540 7,128 ± 1,598 4,405 ± 1,085
E2 759 ± 64b 2,697 ± 663c 3,120 ± 640 1,247 ± 403b 531 ± 134b
IL-6 P 644 ± 48 596 ± 85 475 ± 127 523 ± 81 425 ± 59
E2 469 ± 59b 383 ± 66d 447 ± 57 326 ± 68 227 ± 56b
IL-4 P 337 ± 80 114 ± 12 95 ± 9 120 ± 38 122 ± 48
E2 279 ± 41 90 ± 9 102 ± 12 141 ± 30 102 ± 62
TNFα P 147 ± 27 95 ± 18 105 ± 15 169 ± 32 125 ± 15
E2 190 ± 73 109 ± 31 94 ± 15 122 ± 20 88 ± 22
GM-CSF P 195 ± 22 877 ± 268 1,011 ± 202 430 ± 162 719 ± 361
E2 158 ± 123 1,118 ± 246 826 ± 152 472 ± 189 1,069 ± 229
The cytokine profile was investigated in supernatants of concanavalin A-stimulated spleen cell cultures from experiments 1 (n = 9-10), 2 (n = 12-17), and 3 (n = 8-11)
(see Materials and methods). Values are given as mean ± standard error of the mean. aP <0.01, bP <0.05 versus placebo, Student t test, cP = 0.075, dP = 0.06. E2, estrogen;
Exp., experiment; IFNγ, interferon gamma; IL, interleukin; KO, knockout; P, placebo; GM-CSF, granulocyte macrophage colony-stimulating factor; TNFα, tumor necrosis
factor alpha; WT, wild-type.
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ERα−/− (724%, P <0.001) mice. As seen for total ERα−/−
animals, there were no significant differences between
placebo-treated WT and Col2α1-ERα−/− mice regarding
synovitis or joint destruction, demonstrating that unli-
ganded ERα in chondrocytes is not involved in the
development of AIA. E2 treatment of both WT and
Col2α1-ERα−/− mice decreased bone erosions (−63%
and −59%, respectively; P <0.01) and cartilage degradation
(−66% and −74%, respectively; P <0.05) (Figure 3A,B).
Interestingly, E2 decreased synovitis in WT mice (−28%,
P <0.05) but had no significant effect on synovitis in
Col2α1-ERα−/− animals (Figure 3A,B). These results
suggest that ERα expression in cartilage is involved in
the protective effects of E2 on synovial inflammation
but that ERα in cartilage is dispensable for the effect of
E2 on joint destruction. These results were repeated in
an additional experiment (n = 11-13) with similar results
(data not shown).Figure 3 Estrogen receptor alpha (ERα) in cartilage is involved in the
Histological examination was performed on knee joints from Col2α1-ERα−/− a
with estrogen (E2) (0.83 μg/day) or placebo, to determine effects on infla
and joint destruction. The histological examination was performed by using a sc
Mann-Whitney U test (n = 11-14). (B) Representative images of joint histology. P
macrophages (F480+), (E) T cells (CD3+), and (F) B cells (CD19+) in synovia tissue
(T helper) cells and CD8+ Tc (T cytotoxic) cells in the spleen. *P <0.05, Student
mice with AIA treated with placebo or E2 (0.83 μg/day), after stimulation with th
and results are presented as proliferation index (median of count per minute
wells). *P <0.05, Student t test. Results are shown as mean ± standard error ofFlow cytometry analysis of splenocytes demonstrated
reduced Th cell frequency after E2 treatment in both
WT (−21%, P <0.05) and Col2α1-ERα−/− (−17%, P <0.05)
mice, whereas Tc cells were not affected by E2 treatment
(Figure 3G). E2 decreased the proliferative response in
splenocytes after conA stimulation in WT littermates
(−45%, P <0.05) compared with placebo, and there was a
tendency of decreased proliferative response also in the
Col2α1-ERα−/− mice (−33%, P = 0.06) (Figure 3H). Further-
more, E2 affected the cytokine profile in supernatants of
the spleen cell proliferation cultures similarly in WT and
Col2α1-ERα−/− mice with reduced levels of IL-2, IL-17, and
IFN-γ (Table 1). Thus, ERα expression in cartilage does not
influence the systemic immune response to E2 in AIA.
Synovial cells were investigated by using flow cytometry,
and E2 treatment reduced the monocyte/macrophage
frequency in Col2α1-ERα−/− mice compared with placebo
(−50%, P <0.05), and there was a tendency to decrease
in WT mice compared with placebo (−36%, P = 0.07)estrogenic amelioration of synovitis but not joint destruction.
nd wild-type (WT) littermates with antigen-induced arthritis (AIA), treated
mmation and joint destruction. (A) Histological scoring of synovitis
ale from 1 to 3: 1, mild; 2, moderate; and 3, severe. *P <0.05, **P <0.01,
ercentage of viable (C) neutrophils (CD11b+, Gr1+, F480−), (D) monocytes/
s. *P <0.05, Student t test (n = 6-10). (G) Percentage of viable CD4+ Th
t test (n = 11-14). (H) In vitro proliferation of splenocytes, harvested from
e T-cell mitogen concanavalin A (conA). Cell cultures were set in triplicates,
in wells with conA minus the median of count per minute in control
the mean (n = 11-14).
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frequencies (Figure 3E,F). However, E2 treatment decreased
the neutrophil frequency in WT mice compared with
placebo (−32%, P <0.05), whereas no E2 effect on neutro-
phils was detected in Col2α1-ERα−/− mice compared with
placebo (Figure 3C). A comparison between the placebo-
treated mice showed that the frequency of neutrophils
was significantly decreased in Col2α1-ERα−/− mice com-
pared with WT littermates (−45%, P <0.05). To investigate
the cause of the decreased neutrophil frequency in the
synovia in Col2α1-ERα−/− mice, we analyzed the expres-
sion of neutrophil chemoattractants. Expression of the
neutrophil chemoattractants CXCL1 and CXCL5 was
investigated in the epiphyseal part of the femur, close
to the arthritic joint. E2 treatment did not affect CXCL1
or CXCL5 expression in either WT or Col2α1-ERα−/−
mice (Figure 4A,B). However, the CXCL1 expression was
significantly decreased in Col2α1-ERα−/− mice compared
with WT littermates both after placebo treatment
(−72%, P <0.05) and after E2 treatment (−57%, P <0.05)
(Figure 4A).
The systemic neutrophil migration capability was
investigated in Col2α1-ERα−/− mice and WT littermates
by inducing peritoneal inflammation and investigating
the number of neutrophils in the peritoneal exudate.
The neutrophil count was equal between WT and
Col2α1-ERα−/− mice (Figure 4C), suggesting that there is
no difference in the systemic neutrophil responsiveness in
mice lacking ERα expression specifically in chondrocytes
compared with WT littermates.
Discussion
RA is an autoimmune disease characterized by chronic
inflammation, which leads to destruction of cartilage andA B
Figure 4 Estrogen receptor alpha (ERα) expression in cartilage affects loc
effect on systemic neutrophil migration capacity. Col2α1-ERα−/− and wild-ty
(0.83 μg/day) and induced with antigen-induced arthritis. Expression of (A) Cxcl
gene was adjusted for expression of 18S rRNA. (C) Neutrophil migration was ev
of inflammation in the peritoneal cavity by using uric acid. *P <0.05, Student t tebone loss. Several studies have shown that estrogen exerts
positive effects on arthritis and arthritis-related immune-
mediated bone loss [13,14], but owing to negative side
effects, estrogen is not considered suitable as a long-term
treatment. It is therefore of importance to determine the
mechanism behind its protective effects on arthritis in
order to develop new treatment strategies which retain
the positive, but not the negative, effects of estrogen. We
demonstrate that estrogen (E2) treatment ameliorates
both synovitis and joint destruction in AIA via ERα and
that ERα expression in cartilage cells is dispensable for the
estrogenic protection against joint destruction. Interest-
ingly, our data indicate that ERα expression in cartilage is
involved in the estrogenic effects on synovitis.
Estrogen signaling is complex, involving two classic
nuclear receptors: ERα and ERβ. We and others have
previously reported that activation of ERα, using selective
ERα agonists, decreases the severity of both collagen-
induced arthritis and AIA [5,31,32]. In the present study,
we have used genetically modified mouse models, which
are on a genetic background rendering them relatively in-
sensitive to collagen-induced arthritis, and therefore we
have used AIA as a model of arthritis in order to effect-
ively assess effects on arthritis severity. We show that total
deletion of ERα expression inhibits the protective effects
of E2 on both synovitis and joint destruction, demonstrat-
ing the crucial role of ERα for the ameliorating effect of
estrogen on arthritis in female mice. ERβ activation has
also been implicated to play a role in the amelioration of
arthritis in males [32,33]. However, we and others have
shown, in both female and male rodents, that ERα, and not
ERβ, activation ameliorates arthritis [5,31]. Furthermore, in
the present study, E2 treatment was not able to ameliorate
arthritis in ERα inactivated mice despite the presence ofC
al gene expression of the neutrophil chemokine CXCL1 but has no
pe (WT) littermates were treated with placebo or estrogen (E2)
1 and (B) Cxcl5 in the epiphyseal part of the femur. The mRNA level of each
aluated by analysis of the number of peritoneal exudate cells after induction
st. Results are shown as mean ± standard error of the mean (n = 4-8).
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ing the protective effects of estrogen on arthritis.
T cells are of particular importance in AIA and this is
supported by the fact that nude mice lacking T cells can-
not be induced with AIA [22]. Estrogen affects T lympho-
poiesis, and we and others have previously demonstrated
that estrogenic repression of T lymphopoiesis is mediated
via ERα [27,34]. Estrogen has also been shown to decrease
systemic T lymphocyte proliferation [35], and herein we
confirm these results and establish that expression of ERα
is required for the decreased conA-stimulated splenic T-
cell proliferation. In this study, we demonstrate that E2
decreases the frequency of splenic Th cells via ERα,
whereas Tc cells are unaffected. These results are in ac-
cordance with the notion that AIA is a Th-dependent
disease [22]. Our study shows a clear estrogenic effect
on systemic Th cells found in the spleen, whereas the local
T cells, in the inflamed synovial membrane, are not signifi-
cantly affected. It has previously been reported that sys-
temic, rather than local, counteraction of Th cell function
is responsible for the beneficial effects of Th cell depletion
in the AIA model [36], and we suggest that systemic, ra-
ther than local, effects on Th cells are involved in the
therapeutic efficiency of E2 in AIA. Evaluation of the
cytokines produced by splenocytes treated with the T-
cell mitogen conA demonstrated that E2 treatment re-
duces the levels of IFN-γ, IL-2, IL-6, and IL-17 and that
this reduction is mediated via ERα. These cytokines are all
implicated in the pathogenesis of arthritis [37,38] and
may be involved in the ameliorating effect of estrogen
on arthritis. AIA is not dependent on B cells, except in
very severe cases [23]. Accordingly, we found that nei-
ther antigen-specific antibodies nor the B-cell fre-
quency in synovia was associated with the estrogenic
amelioration of arthritis.
The role of chondrocytes in the pathogenesis of arth-
ritis has gained increasing interest. The recent finding
that synovial fluid from patients with RA triggers secre-
tion of various cytokines from chondrocytes, including
cytokines involved in chemotactic migration of immune
cells, suggests that these cells can actively take part in
inflammatory joint diseases and not just be passive par-
ticipators, as previously believed [39,40]. Chondrocytes
express ERs, and estrogen can affect protein production
in these cells [16]. We have recently shown that ERα
expression in cartilage is important for the reduction of
growth plate height induced by high E2 levels in adult
mice, using a cartilage-specific ERα inactivated mouse
model (Col2α1-ERα−/− mice) [25]. In this study, we used
the Col2α1-ERα−/− mice to determine the importance
of cartilage-specific ERα expression for the ameliorating
effects of estrogen on arthritis. E2 treatment of Col2α1-
ERα−/− mice resulted in a similar reduction in joint
destruction as seen in WT littermates, demonstrating thatERα expression in chondrocytes is not involved in the
estrogenic protection against joint destruction. Interest-
ingly, E2 treatment did not significantly reduce the synovial
inflammation in mice lacking ERα expression in chondro-
cytes, suggesting different target cells and mechanisms
for the estrogenic protection against synovial inflamma-
tion and joint destruction. Dissociation between synovial
inflammation and joint destruction has been described
before where treatments have provided protection against
bone erosions despite continuous synovial inflammation
[41], and progression of bone erosions has been detected
despite improvement of inflammatory scores [42]. In an
attempt to understand the mechanism behind the lack
of estrogenic response on synovial inflammation in
Col2α1-ERα−/− mice, we examined synovial cell popula-
tions. Synovial monocytes/macrophages and neutrophils
are known to be important in RA and produce cytokines
and chemokines that attract and further activate the
immune system [43,44], and estrogen regulates both
the number and function of neutrophils as well as
reduces neutrophil chemotaxis [45]. We show that E2
treatment reduced the frequency of monocytes/macro-
phages in the joints both in WT littermates and in
Col2α1-ERα−/− mice. In contrast, E2 treatment was
only able to decrease the frequency of neutrophils in
the joints of WT littermates, whereas the neutrophils
were unaffected by E2 treatment in mice lacking ERα
expression in chondrocytes. Thus, the inability of E2 to
significantly decrease synovitis in mice lacking ERα
expression in cartilage cells may depend on the lack of
E2 effect on neutrophils. The lack of E2 effect on neutro-
phils might be influenced by the fact that the number of
neutrophils in the placebo-treated cartilage-specific ERα
inactivated mice compared with the placebo-treated WT
mice was significantly lower, suggesting that ERα expres-
sion in cartilage might be involved in the migration of neu-
trophils. Accordingly, we found that expression of the
neutrophil chemokine CXCL1 [46,47], known to be
expressed in chondrocytes [48,49], was decreased in the
Col2α1-ERα−/− mice, whereas no significant difference
was detected in the expression of the neutrophil chemo-
kine CXCL5, known to be expressed in cells of the mye-
loid lineage, including monocytes and osteoclasts [50].
Our data indicate that ERα expression in chondrocytes
is required for normal expression of CXCL1 and thus for
normal local migration of neutrophils into the joint. In
addition, we found no differences in the systemic neutro-
phil responsiveness in the Col2α1-ERα−/− mice, which indi-
cates that only the local migration of neutrophils into the
arthritic joint is altered in the Col2α1-ERα−/− mice.
Conclusions
ERα is required for the protective effects of estrogen treat-
ment of AIA in ovx animals. Furthermore, ERα expression
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of joint destruction. However, our data indicate that
ERα expression in cartilage is involved in estrogenic
effects on synovitis by influencing neutrophil migration,
suggesting different mechanisms for the amelioration of
joint destruction and synovitis by E2. Increased know-
ledge about the mechanisms behind the beneficial effects
of estrogen is useful in the search for novel treatments
against arthritis.
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